Novo Nordisk's Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease

(NYSE:NVO) Compared with tirzepatide, Wegovy® (semaglutide) 2.4 mg showed a significant 57% greater reduction in the risk of heart attack, stroke or death from any cause, in people with overweight or obesity and cardiovascular disease (CVD) while on treatment1 Similarly, the study showed a...